reports
Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicine...
Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Genetic Medicines Virtual Conference on Tuesday, October 14, 2025. Company management will host virtual...
Tenaya Therapeutics to Participate in Upcoming October Investor Confer...
Tenaya Therapeutics to Participate in Upcoming October Investor Conferences SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in the following October investor and industry conferences. Details are below: Cell & Gene Meeting on the Mesa Date: Monday, October 6Time: 8:00 AM MT – 9:00 A...
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rul...
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 202,000 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment. The stock options have an exerci...
Consumer Portfolio Services Inc: 2 directors
Two Directors at Consumer Portfolio Services Inc sold after exercising options/sold 109,369 shares at between 8.494USD and 8.620USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary tr...
UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascend...
UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and efficacy in nAMD patients receiving four initial monthly doses of TH103 Phase 1b/2 study to inform dose selection for potential Phase 3 development program, with initial data expected in 2H 2026 TH103’s ongoing Phase 1a single ascending dose study remains on track for data to be reported in Q4 2025 PALO ALTO, Calif., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Kalari...
Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose ...
Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and preliminary efficacy in nAMD patients receiving up to four initial monthly doses of TH103 Phase 1b/2 study to inform dose selection for potential Phase 3 development program, with initial data expected in 2H 2026 TH103’s ongoing Phase 1a single ascending dose study remains on track for data to be reported in Q4 2025 PALO ALTO, Calif., Sept. 15, 2025 (GLOBE NEWS...
HVIP Is Back: Here’s What California Fleets Need to Know (And Why It M...
HVIP Is Back: Here’s What California Fleets Need to Know (And Why It Matters Now) Xos, Inc. explains how it helps California fleets navigate HVIP and maximize funding for electric trucks LOS ANGELES, Sept. 10, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: XOS) - The Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project (HVIP) is officially back, and California fleets have a major opportunity to secure funding for electric trucks. Depending on fleet size, incentives range from $85,000 to $160,000 per Class 6 vehicle, with up to 20 vouchers available per fleet. On September 9, 2025, the C...
Windrose and Xos Partner to Deliver Game-Changing Charging Access for ...
Windrose and Xos Partner to Deliver Game-Changing Charging Access for Class 8 Electric Fleets LOS ANGELES, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Windrose, manufacturer of one of the lightest and longest-range electric Class 8 trucks in the world, is partnering with Xos (NASDAQ: XOS), a leading provider of mobile charging solutions, to bring powerful, scalable charging to fleet operators across the United States and international markets. Windrose's Class 8 electric truck is engineered from the ground up for global deployment across 6 markets: North America, Europe, South America, Oceania, A...
MacroGenics to Present at H.C. Wainwright 27th Annual Global Investmen...
MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference ROCKVILLE, MD, Sept. 02, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that MacroGenics’ President & Chief Executive Officer, Eric Risser, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 11:30am ET in New York, NY. A webcast of the above presentation may be accessed under "Events & Presentations" in t...
Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual G...
Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50 pm ET. The live...
Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural Histor...
Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025 Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants 93% of MyClimb Participants had the Nonobstructive Form of HCM for Which There Are No Approved Therapeutics Genotypic Status Identified as a Significant Predictor of Risk and Left Ventricular Mass Index May Serve as a Surrogate Marker for Poor Long-Term Outcomes SOUTH SAN FRANCIS...
Consumer Portfolio Services to Present at the 2025 Gateway Conference ...
Consumer Portfolio Services to Present at the 2025 Gateway Conference on September 3rd LAS VEGAS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”), a leader in providing indirect automobile financing to consumers, is confirmed to present at the , which is being held September 3–4 at the in San Francisco, CA. CPS’ management team is scheduled to present on Wednesday, September 3rd at 1:30 p.m. Pacific Time (PT). The presentation will be webcast live and available for replay . In addition to the presentation, CPS executives ...
- Jonathan Moreland
PRGO PERRIGO CO. PLC
POST POST HOLDINGS INC.
MGNX MACROGENICS INC.
MERC MERCER INTERNATIONAL INC.
LOB LIVE OAK BANCSHARES
HTH HILLTOP HOLDINGS INC.
HNRG HALLADOR ENERGY CO.
GLP GLOBAL PARTNERS LP
DIN DINE BRANDS GLOBAL INC.
CE CELANESE CORPORATION
QRHC QUEST RESOURCE HOLDING
HTLD HEARTLAND EXPRESS INC.
RSG REPUBLIC SERVICES INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
BSM BLACK STONE MINERALS LP
NTLA INTELLIA THERAPEUTICS INC.
CYRX CRYOPORT INC.
SD SANDRIDGE ENERGY INC.
ECIA ENCISION INC
UA UNDER ARMOUR
EOLS INC.
CCEL EVOLUS INC
ULBI CRYO-CELL INTERNATIONAL
AVTR ULTRALIFE
EPSN AVANTOR
ASAN INC.
OPCH EPSILON ENERGY LIMITED
MYO ASANA
ATAI OPTION CARE HEALTH INC
PFHC MYOMO
OPAL ATAI LIFE SCIENCES BV
CALC PROFRAC HLDG CORP
ET OPAL FUELS INC
PROP CALCIMEDICA INC.
FIP ENERGY TRANSFER LP
MDRR PRAIRIE OPERATING CO.
ECF FTAI INFRASTRUCTURE INC
LNW MEDALIST DIVERSIFIED REIT INC.
NUGN ELLSWORTH FUND LTD
EFOI LIGHT & WONDER INC.
SST LIVENTO GROUP
STRZ INC.
ENERGY FOCUS INC.
SYSTEM1 INC
STARZ ENTERTAINMENT CORP
Xos, Inc. Appoints Automotive Veteran John Smith to its Board of Direc...
Xos, Inc. Appoints Automotive Veteran John Smith to its Board of Directors Former General Motors Group Vice President brings decades of global automotive, strategy, and governance experience as Xos scales MDXT and charging solutions LOS ANGELES, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Xos, Inc., a leading manufacturer of medium‑duty electric vehicles and mobile charging solutions, today announced that John F Smith has been appointed to the Company’s Board of Directors, effective August 18, 2025. With Mr. Smith’s appointment, the Board has increased from eight to nine directors. Mr. Smith has ...
Macrogenics Inc: 1 director
A director at Macrogenics Inc bought 100,000 shares at 1.505USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
PCTY PAYLOCITY HOLDING CORP.
LNTH LANTHEUS HOLDINGS INC
HUBS HUBSPOT INC.
HAE HAEMONETICS CORPORATION
CRM SALESFORCE.COM INC.
CRK COMSTOCK RESOURCES INC.
CPRX CATALYST PHARMACEUTICALS
AR ANTERO RESOURCES CORPORATION
HRB H&R BLOCK INC.
SNAP SNAP INC. CLASS A
CNX CNX RESOURCES CORPORATION
ACI-R-A ADRIATIC CROATIA INTERNATIONAL CLUB D.D.
HPK HIGHPEAK ENERGY INC (A)
ACVA ACV AUCTIONS INC
CHK CHESAPEAKE ENERGY CORP
BRZE BRAZE INC
SG SWEETGREEN INC
MNDY MONDAY COM LTD
IOT SAMSARA INC
KLC KINDERCARE LEARNING COS INC
TEAM ATLASSIAN CORPORATION
SLDE SLIDE INS HLDG INC
Xos Breaks the $100K Barrier for High-Powered Mobile Charging with New...
Xos Breaks the $100K Barrier for High-Powered Mobile Charging with New Hub Approved for $110,000 CORE Incentive LOS ANGELES, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Xos, Inc. (NASDAQ: XOS) announced today that the newest version of its mobile charging unit, the Xos Hub™, has been approved for California’s Clean Off-Road Equipment (CORE) Voucher Incentive Project, making it eligible for a . This groundbreaking approval means the Xos Hub is now available for under $100,000, less than half the cost of many equivalent DC fast charging systems, which often exceed $200,000. The result is a major le...
MacroGenics Reports Second Quarter 2025 Financial Results and Highligh...
MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities Newly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement for ZYNYZ® Cash, cash equivalents and marketable securities of $176.5 million as of June 30, 2025; cash runway through first half of 2027 ROCKVILLE, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing inn...
Xos Hits New Milestones in Q2 2025 with Highest Revenue and Deliveries...
Xos Hits New Milestones in Q2 2025 with Highest Revenue and Deliveries in the Company’s History Reduced year-over-year operating expenses by $4.7 million and posted lowest operating loss as a public company in the second quarter of 2025 Generated positive net cash provided by operating activities of $4.6 million in the second quarter of 2025 LOS ANGELES, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Xos, Inc. (NASDAQ: XOS) (“Xos” or the “Company”), a leader in electric commercial vehicles and mobile charging solutions, today announced a breakout quarter by a number of measures. In t...
MacroGenics Appoints Eric Risser as President and Chief Executive Offi...
MacroGenics Appoints Eric Risser as President and Chief Executive Officer ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of August 13, 2025, Eric Risser has been appointed President, Chief Executive Officer and to the Board of Directors. Mr. Risser has served as Chief Operating Officer at MacroGenics since 2022, overseeing several key company functions and has led the Company’s corporate development...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.